Roses RE - Search Results

1

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

Datta J, Berk E, Cintolo JA, Xu S, Roses RE, Czerniecki BJ. Datta J, et al. Among authors: roses re. Front Immunol. 2015 Jun 2;6:271. doi: 10.3389/fimmu.2015.00271. eCollection 2015. Front Immunol. 2015. PMID: 26082780 Free PMC article. Review.

2

Development of vaccines for high-risk ductal carcinoma in situ of the breast.

Czerniecki BJ, Roses RE, Koski GK. Czerniecki BJ, et al. Among authors: roses re. Cancer Res. 2007 Jul 15;67(14):6531-4. doi: 10.1158/0008-5472.CAN-07-0878. Cancer Res. 2007. PMID: 17638860 Review.

3

Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer.

Roses RE, Xu M, Koski GK, Czerniecki BJ. Roses RE, et al. Oncogene. 2008 Jan 7;27(2):200-7. doi: 10.1038/sj.onc.1210909. Oncogene. 2008. PMID: 18176601 Review.

4

Reengineering dendritic cell-based anti-cancer vaccines.

Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Koski GK, et al. Among authors: roses re. Immunol Rev. 2008 Apr;222:256-76. doi: 10.1111/j.1600-065X.2008.00617.x. Immunol Rev. 2008. PMID: 18364007 Review.

5

Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists.

Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ. Roses RE, et al. J Immunol. 2008 Oct 1;181(7):5120-7. doi: 10.4049/jimmunol.181.7.5120. J Immunol. 2008. PMID: 18802116

6

HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer.

Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, Fox KR, Zhang PJ, Czerniecki BJ. Roses RE, et al. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1386-9. doi: 10.1158/1055-9965.EPI-08-1101. Epub 2009 Apr 21. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19383888 Free PMC article.

7

Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu-pulsed dendritic cell vaccines.

Bahl S, Roses RE, Sharma A, Koldovsky U, Xu S, Weinstein S, Nisenbaum H, Fox K, Pasha T, Zhang P, Araujo L, Carver J, Czerniecki BJ. Bahl S, et al. Among authors: roses re. Am J Surg. 2009 Oct;198(4):488-94. doi: 10.1016/j.amjsurg.2009.06.014. Am J Surg. 2009. PMID: 19800453 Free PMC article.

8

The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.

Harada S, Mick R, Roses RE, Graves H, Niu H, Sharma A, Schueller JE, Nisenbaum H, Czerniecki BJ, Zhang PJ. Harada S, et al. Among authors: roses re. J Surg Oncol. 2011 Oct;104(5):458-65. doi: 10.1002/jso.21973. Epub 2011 May 9. J Surg Oncol. 2011. PMID: 21557226 Free PMC article.

9

HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ. Sharma A, et al. Cancer. 2012 Sep 1;118(17):4354-62. doi: 10.1002/cncr.26734. Epub 2012 Jan 17. Cancer. 2012. PMID: 22252842 Free PMC article. Clinical Trial.

10

Sartorius transposition during inguinal lymphadenectomy for melanoma.

Bartlett EK, Meise C, Bansal N, Fischer JP, Low DW, Czerniecki BJ, Roses RE, Fraker DL, Kelz RR, Karakousis GC. Bartlett EK, et al. Among authors: roses re. J Surg Res. 2013 Sep;184(1):209-15. doi: 10.1016/j.jss.2013.04.033. Epub 2013 May 8. J Surg Res. 2013. PMID: 23688786

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

149 results

Search Page